Literature DB >> 17165086

Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma.

Mirosław Szczepański1, Maria Stelmachowska, Lukasz Stryczyński, Wojciech Golusiński, Husam Samara, Iwona Mozer-Lisewska, Jan Zeromski.   

Abstract

Head and neck cancers remain a big challenge for oncology. Among them laryngeal carcinomas predominate. In spite of abundant inflammatory cell infiltrates containing several immunologically competent cells, patients with head and neck cancers show markedly suppressed anti-tumor response. In general, cancer cells use strategies to avoid recognition and destruction by the immune system. Toll-like receptors 1-13 (TLRs) are crucial for activation of innate immunity and secondarily for the induction of acquired response. TLRs are mainly expressed on cells of the immune system, but they have been demonstrated on endothelial and epithelial cells. Ligand binding to TLR leads to the activation of several genes, predominantly proinflammatory ones such as IL-1 and TNF-alpha and maturation of professional antigen presenting cells (APC) i.e., dendritic cells. It can cause better tumor antigen presentation by APC. The aim of this study was the evaluation of expression of TLR-2, TLR-3 and TLR-4 in the microenvironment of laryngeal carcinoma. Tumor specimens (n = 20, male patients aged 43-77 years, mean 57 years) from patients subjected to total laryngectomy. Immunohistochemistry and indirect immunoflourescence on frozen tissue sections. Cancer tissue: portion of cancer cells manifested membrane and/or cytoplasmic expression of TLR-2, TLR-3 and TLR-4. The most frequent expression on tumor cells was TLR-2 and the least expression of TLR-4. Inflammatory infiltrates: in all cases inflammatory cell infiltrates of various intensities were present, both in tumor mass and tumor stroma. Expression of all TLRs tested, both, membrane and cytoplasmic ones were shown on inflammatory cells, but distinct in quantitative terms. TLR-4 positive cells were the most frequent. A portion of cells expressed both, TLR and HLA-DR. It is of interest that TLRs tested were expressed not only on cells of inflammatory infiltrate, but also on tumor cells. This fact may be an important factor in tumor escape from immune surveillance. It is notable, that both, TLRs and HLA-DR were shown to be co-expressed, what may favor the role and impact of TLRs in antigen presentation. Further studies are needed to elucidate TLRs function in the course of neoplastic process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17165086     DOI: 10.1007/s00405-006-0215-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  19 in total

1.  Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex.

Authors:  K Ohashi; V Burkart; S Flohé; H Kolb
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

2.  Tissue localization of Toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus.

Authors:  I Mozer-Lisewska; W Sluzewski; M Kaczmarek; R Jenek; M Szczepanski; M Figlerowicz; A Kowala-Piaskowska; J Zeromski
Journal:  Scand J Immunol       Date:  2005-10       Impact factor: 3.487

3.  Toll-like receptors on tumor cells facilitate evasion of immune surveillance.

Authors:  Bo Huang; Jie Zhao; Hongxing Li; Kai-Li He; Yibang Chen; Shu-Hsia Chen; Lloyd Mayer; Jay C Unkeless; Huabao Xiong
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

4.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.

Authors:  R Medzhitov; P Preston-Hurlburt; C A Janeway
Journal:  Nature       Date:  1997-07-24       Impact factor: 49.962

5.  Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

Authors:  A F Carpentier; L Chen; F Maltonti; J Y Delattre
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

6.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

7.  Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.

Authors:  Evelyn Hartmann; Barbara Wollenberg; Simon Rothenfusser; Moritz Wagner; Daniela Wellisch; Brigitte Mack; Thomas Giese; Olivier Gires; Stefan Endres; Gunther Hartmann
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

8.  Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent.

Authors:  Martha Triantafilou; Maria Manukyan; Alan Mackie; Siegfried Morath; Thomas Hartung; Holger Heine; Kathy Triantafilou
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

Review 9.  Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?

Authors:  Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2004-04-29       Impact factor: 6.968

10.  Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.

Authors:  Klaus Heckelsmiller; Sebastian Beck; Katharina Rall; Bence Sipos; Angelika Schlamp; Evelyn Tuma; Simon Rothenfusser; Stefan Endres; Gunther Hartmann
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

View more
  15 in total

Review 1.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

Review 2.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 3.  TLR4 Polymorphisms and Expression in Solid Cancers.

Authors:  Nilesh Pandey; Alex Chauhan; Neeraj Jain
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

4.  Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

Authors:  Miroslaw J Szczepanski; Malgorzata Czystowska; Marta Szajnik; Malgorzata Harasymczuk; Michael Boyiadzis; Aleksandra Kruk-Zagajewska; Witold Szyfter; Jan Zeromski; Theresa L Whiteside
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

Review 5.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

6.  Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma.

Authors:  L K Ng; A M Rich; H M Hussaini; W M Thomson; A L Fisher; L S Horne; G J Seymour
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

Review 7.  Toll-like receptor 4 activation in cancer progression and therapy.

Authors:  Alja Oblak; Roman Jerala
Journal:  Clin Dev Immunol       Date:  2011-11-03

8.  Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients.

Authors:  Beda Muehleisen; Shang Brian Jiang; Julie A Gladsjo; Monika Gerber; Tissa Hata; Richard L Gallo
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

9.  Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment.

Authors:  Yusuke Sato; Yasufumi Goto; Norihiko Narita; Dave S B Hoon
Journal:  Cancer Microenviron       Date:  2009-08-15

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.